Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Ended early

IR4FTD Discovery of new Frontal Temporal Dementia multimodal spectral markers in biofluids.

Coordinator
International Centre for Genetic Engineering and Biotechnology, Italy
Runs
1 October 2023 to 30 September 2026
Status
Ended early
EU funding
€287k
Total cost
—
Partners
3 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101106307

What the project is doing

In the project's own words, from its summary on CORDIS.

The central aim of the project is to apply multimodal spectroscopy combined with machine learning to identify a fingerprint for Frontal Temporal Dementia (FTD) and Alzheimer’s disease (AD) in saliva and plasma. FTD is the second most common dementia and usually affects individuals younger than 60 years old. FTD is difficult to diagnose, since there is no single exam that determines the disease, but instead many costly or painful exams that together link the disease.

Some of the symptoms of the disease may be confounding with others such as AD. While the usual search for biomarkers focuses on individual patterns, the present proposal is to use a holistic approach. Vibrational spectroscopy provides a snapshot of the entire chemical finger print in a label-free way. In this project, samples from FTD, AD, and healthy subjects of >45 years old, will be analysed using Raman, mid and near infrared spectroscopy @Monash University in Australia, and complemented with Mass Spectrometry on the same samples @ICGEB in Italy.

Advanced machine learning tools provide a powerful approach for data analysis unravelling hidden trends, correlations and also identify the main contributions that characterize the type of sample. The spectra recorded using the extended wavelength range encompassing the mid-infrared and near-infrared spectral regions will be processed with state-of-the-art machine learning tools to identify the molecular phenotype and establish markers in patients with TDP and AD.

These findings will pave the way to the development of a new screening tool that would decrease the costs associated with the current diagnosis of FTD and in general for neurodegenerative disorders.

Topics

Who is involved

OrganisationCityCountryRole
International Centre for Genetic Engineering and BiotechnologyTriesteItalyCoordinator
Monash UniversityVictoriaAustraliaAssociatedpartner
Elettra - Sincrotrone Trieste ScpaBasovizza TriesteItalyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI